Olfr1111 is a member of the olfactory receptor gene family. Olfactory receptors are part of a large family of G protein-coupled receptors (GPCRs) involved in odor detection. G protein-coupled receptors (GPCRs) represent the largest and most diverse group of membrane receptors in eukaryotes. These receptors are involved in an array of physiological processes, making them key targets in drug discovery. GPCR inhibitors, therefore, encompass a broad range of chemicals that modulate the activity of these receptors through various mechanisms. Some inhibitors, like suramin and propranolol, act by directly binding to the receptor, blocking the interaction with their natural ligands. Others, such as losartan, are selective antagonists for specific receptor subtypes, providing a more targeted approach to inhibition. The complexity of GPCR signaling pathways offers multiple targets for inhibition. Compounds like Y-27632, SB 203580, and U0126 do not directly target the receptors but rather inhibit the downstream signaling molecules such as kinases (ROCK, MAPK, MEK). This type of inhibition affects the intracellular responses elicited by GPCR activation, effectively modulating the receptor's overall function. For example, PI3K inhibitors like LY294002 and wortmannin disrupt the PI3K/Akt pathway, a crucial signaling route for many GPCRs, thereby indirectly influencing receptor activity.
Moreover, the pharmacological modulation of GPCRs is not limited to antagonism. Compounds like BIM-23127, though classified as an agonist, can provide valuable insights into receptor dynamics and regulation. By activating certain receptors, these compounds can induce a regulatory feedback mechanism, potentially leading to receptor desensitization or internalization, which indirectly reduces receptor activity. The use of pan-inhibitors like Go6983, which target a family of kinases such as PKC, highlights the strategy of broad-spectrum inhibition, affecting multiple receptors and signaling pathways simultaneously. In summary, GPCR inhibitors comprise a diverse array of chemical entities, each with unique mechanisms of action. Their ability to interfere with GPCR signaling at various levels – from ligand binding to downstream effector pathways – makes them invaluable tools in the study of GPCR function and regulation, including the indirect modulation of specific receptors like Olfr1111.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
A non-selective antagonist of G protein-coupled purinergic receptors, which may affect GPCR signaling indirectly. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A non-selective beta-adrenergic receptor antagonist, potentially influencing GPCR-mediated pathways. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
An angiotensin II receptor antagonist, it may indirectly affect GPCR signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor, indirectly affecting GPCR signaling through the Rho/ROCK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK, potentially modulating GPCR downstream signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK1/2, possibly affecting GPCR signaling through the ERK pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor, potentially modulating GPCR signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, which may indirectly influence GPCR signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor, which can affect GPCR signaling pathways. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
A PKC inhibitor, potentially influencing GPCR-mediated cellular responses. | ||||||